Registration Strip Icon for charts 登録してリアルタイムのチャート、分析ツール、価格を入手してください。

RXRX

Recursion Pharmaceuticals (RXRX)

Recursion Pharmaceuticals Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:RXRX
日付受信時刻ニュースソース見出しコード企業名
2025/01/0900 : 30Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
2025/01/0723 : 15GlobeNewswire Inc.Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & MoreNASDAQ:RXRXRecursion Pharmaceuticals Inc
2025/01/0708 : 02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
2025/01/0708 : 02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
2025/01/0708 : 02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
2025/01/0622 : 30GlobeNewswire Inc.Recursion to Present at 43rd Annual JP Morgan Healthcare ConferenceNASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/12/2706 : 24Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/12/2106 : 16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/12/2106 : 05GlobeNewswire Inc.Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing RulesNASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/12/1908 : 49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/12/1807 : 06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/12/1807 : 05Edgar (US Regulatory)Form 424B7 - Prospectus [Rule 424(b)(7)]NASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/12/1206 : 48Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/12/1106 : 56Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/12/1008 : 00GlobeNewswire Inc.Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable TolerabilityNASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/12/0707 : 46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/12/0600 : 29Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/12/0500 : 32Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/12/0406 : 40Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/12/0322 : 30GlobeNewswire Inc.Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and LymphomaNASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/12/0309 : 02Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/11/2806 : 09Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/11/2706 : 48Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/11/2308 : 25Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/11/2308 : 25Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/11/2206 : 24Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/11/2021 : 14Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/11/2021 : 11Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/11/2021 : 00GlobeNewswire Inc.Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discoveryNASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/11/2008 : 26Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:RXRX

最近閲覧した銘柄

Delayed Upgrade Clock